Latest Bioavailability Stories
CUPERTINO, Calif., May 18, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral
Trivedi Science™ is on the verge of creating highly advanced pharmaceutical compounds with the potential for a longer shelf life, greater solubility and bioavailability, increased drug efficacy,
PARSIPPANY, N.J., April 15, 2015 /PRNewswire/ -- Close to 40% of the currently marketed drugs fall into the two low solubility Biopharmaceutical Classification System (BCS) categories; furthermore,
CUPERTINO, Calif., March 30, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928,
HONG KONG, Feb.
A team of senior drug development and delivery experts from Catalent Pharma Solutions (Booth 1414), will lead multiple thought-leadership discussions, present scientific papers, and exhibit at
OMICS Group International schedules its 5th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit during September 29 to October 01, 2014 at Baltimore, USA with an
Innovative Technology and Pharmacokinetic (PK) Studies Lead Path to CBD efficacy. NEWARK, N.J., Aug. 5, 2014 /PRNewswire/ -- Inergetics, Inc.
Dignity Sciences Limited finds that orally administered DGLA distributes well to the skin resulting in high dermal bioavailability Dublin, Ireland (PRWEB) July
FALLS CHURCH, Va., July 11, 2014 /PRNewswire/ -- Poor bioavailability is a major reason for compounds to fail in preclinical development.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).